| Factor Information | |
|---|---|
| Data ID | 3274 |
| Factor | arterial saturation (mean(SD)) |
| Description | N/A |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | treatment evaluation |
| Objective | To examine long-term safety and efficacy of bosentan—an oral dual endothelin receptor antagonist—in patients with pulmonary hypertension associated with congenital heart disease or Eisenmenger’s syndrome. |
| p Value | 0.014 |
| Conclusion | Mean (SD) functional class (p = 0.001) and the 6-minute walk test distance improved compared with baseline (284 (144) vs 363 (124) m, 380 (91) m and 408 (114) m at baseline, 0–6 months, 6–12 months and 1–2 years of treatment, respectively; p<0.05 for each). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 667 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | ASD/VSD/PAD/AP window/AVSD/SV |
| Reference | |
|---|---|
| PMID | 17639112 |
| Year | 2007 |
| Title | Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | patients' data | |
| Region | London, United Kindom | |
| Method | χ2 statistics | |
| Race | British | |
| Disease History | N/A | |
| Treatment History | treated with bosentan | |
| Group | PAH patients associated with CHD treated with bosentan after 0-6months(Treatment) | baseline (untreated)(Control) |
| Number | 15 | N/A |
| Age | mean(SD)=41(9) years | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 84.7(2.6)% | 81.1(4.9)% |
